

Fiscal Year:	FY 2022	Task Last Updated: FY 01/25/2022	
PI Name:	Smith, Scott M Ph.D.		
Project Title:	Astronaut Vision Issues and One Carbon Metabolism: Expanded Polymorphism Evaluation and Evaluation in a Potential Analog Population		
Division Name:	Human Research		
Program/Discipline:			
Program/Discipline--Element/Subdiscipline:	HUMAN RESEARCH--Biomedical countermeasures		
Joint Agency Name:	TechPort:	No	
Human Research Program Elements:	(1) HHC: Human Health Countermeasures		
Human Research Program Risks:	(1) SANS: Risk of Spaceflight Associated Neuro-ocular Syndrome (SANS)		
Space Biology Element:	None		
Space Biology Cross-Element Discipline:	None		
Space Biology Special Category:	None		
PI Email:	scott.m.smith@nasa.gov	Fax: FY 281-483-2888	
PI Organization Type:	NASA CENTER	Phone: 281-483-7204	
Organization Name:	NASA Johnson Space Center		
PI Address 1:	Biomedical Research and Environmental Sciences Division/SK3		
PI Address 2:	2101 NASA Pkwy		
PI Web Page:			
City:	Houston	State: TX	
Zip Code:	77058-3607	Congressional District: 36	
Comments:			
Project Type:	Flight,Ground	Solicitation / Funding Source: Directed Research	
Start Date:	04/06/2016	End Date: 09/30/2023	
No. of Post Docs:	No. of PhD Degrees:		
No. of PhD Candidates:	No. of Master' Degrees:		
No. of Master's Candidates:	No. of Bachelor's Degrees:		
No. of Bachelor's Candidates:	Monitoring Center: NASA JSC		
Contact Monitor:	Brocato, Becky	Contact Phone:	
Contact Email:	becky.brocato@nasa.gov		
Flight Program:			
Flight Assignment:	NOTE: End date changed to 9/30/23 per C. Ribeiro/HHC HRP (Ed., 8/26/22) NOTE: End date changed to 9/30/22 per C. Ribeiro/HHC HRP (Ed., 6/30/21) NOTE: End date changed to 10/01/2021 per PI (Ed., 1/7/21) NOTE: End date changed to 12/31/2020 per PI (Ed., 1/9/2020) NOTE: Extended to 4/30/2020 per PI (Ed., 1/28/19)		
Key Personnel Changes/Previous PI:			
COI Name (Institution):	Zwart, Sara Ph.D. (University of Texas Medical Branch) Chang, Alice M.D. (Mayo Clinic, Rochester, MN) Gregory, Jesse Ph.D. (University of Florida) Chen, John M.D., Ph.D. (Mayo Clinic, Rochester, MN) Zeisel, Steven M.D., Ph.D. (University of North Carolina at Chapel Hill) Gibson, C. Robert O.D. (Coastal Eye Associates) Mader, Thomas M.D. (U.S. Army (retired))		
Grant/Contract No.:	Directed Research		

Performance Goal No.:	
Performance Goal Text:	
Task Description:	<p>Background We have documented a genetic predisposition for some astronauts to develop ophthalmologic issues. From a limited study of 5 single-nucleotide polymorphisms (SNPs), we found one SNP associated with a greater risk of ophthalmic findings (e.g., choroidal folds, cotton wool spots), and another SNP that was protective against optic disc edema. In light of these findings, we proposed two studies which were combined in this project. Thus, this project has two major goals:</p> <ol style="list-style-type: none"> 1. To extend the one-carbon pathway SNP assessment as related to astronaut ophthalmologic findings. (One Carbon Expansion study) 2. To evaluate patients with polycystic ovary syndrome (PCOS) and/or Idiopathic intracranial hypertension (IIH) to assess one-carbon biochemistry and genetics and their possible correlation with ophthalmologic findings. (PCOS study) <p>While these studies alone will not identify the mechanism(s) of astronaut ophthalmologic issues, we aim to clarify the genetic relationship to ophthalmic findings, and to document the utility of PCOS as a clinical population that could be used for studies that may ultimately allow for the definition of the mechanism of and means to prevent or treat these potentially vision-threatening processes in astronauts.</p> <p>Specific Aims The study has the following specific aims:</p> <ol style="list-style-type: none"> 1. Test for multiple SNPs of the 85 major genes involved in one-carbon metabolism in ISS (International Space Station) crewmembers (a total of 523 SNPs), and relate these data to existing one-carbon biochemistry and metabolomic data, along with existing vision and related medical data. 2. Compare the same one-carbon metabolism genetics and biochemistry and ophthalmologic data from patients in one of four treatment groups: <ol style="list-style-type: none"> i. women diagnosed with PCOS without IIH ii. women diagnosed with PCOS and IIH iii. women diagnosed with IIH without PCOS iv. controls (neither PCOS nor IIH)
Rationale for HRP Directed Research:	<p>This research is directed because it contains highly constrained research. This study has two major goals: 1. To utilize existing samples where possible to extend the scope of the initial One Carbon study. This was initially submitted and reviewed in the NNJ14ZSA001N-OMNIBUS NRA. HRP Management has now asked we submit this as directed research. 2. To add testing to an ongoing clinical trial at the Mayo Clinic. Timing is critical given that study is ongoing. The primary study is a clinical trial of pharmaceutical treatment for PCOS. We propose to extend this study by collecting a blood sample for one carbon biochemical and genetic testing, along with ophthalmologic exams, with the aim of documenting the utility of this population as an analog group for future VIIP research.</p>
Research Impact/Earth Benefits:	<p>While much research is in progress to understand vision issues in astronauts, a key question remains as to why only some individuals are affected. Our preliminary data suggest that some individuals may have a genetic predisposition for vision issues, related to one-carbon metabolism. Our initial study was intentionally constrained given our concerns about it being the first study involving individual genetic testing at NASA. In light of the crewmember response to that study (>97% participation) and the initial findings from that effort, we now propose to evaluate a wider range of one-carbon metabolism SNPs, to help clarify and verify that one-carbon metabolism is indeed the source of this effect, and to identify possible associations with ethnicity. The results of this study could be profound, and may have significant implications for the direction of NASA vision countermeasure research, for operational decisions regarding treatment of affected astronauts, and for informing the general medical and scientific communities, where research is ongoing to understand the role of one-carbon metabolism genetics in other cerebrovascular issues.</p>
Task Progress:	<p>One Carbon Expansion study: After receiving Authority to Proceed (ATP) on April 6, 2016, the Institutional Review Board (IRB) documentation was developed and submitted for review. IRB approval was obtained in May 2016. With a concerted effort from NASA International Space Station Medical Project/Research Operations and Integration (ISSMP/ROI) starting in August 2018, a large number of consents were obtained. As of this writing, we have consents from 79 crewmembers.</p> <p>We had hoped to be able to recruit the remaining 15 or so crewmembers that were planned for inclusion in the proposal. ATP was granted for 8 of those crewmembers in May 2021. As of January 2022, we have received consent and blood collection from one of those 8, and a second is being scheduled.</p> <p>We are working with Dr. Geoffrey Ginsburg's group at Duke University to conduct statistical analyses of the genetic, biochemical, and ocular findings from this study. Initial findings were reported at the 2021 NASA Human Research Program Investigators' Workshop (HRP IWS) meeting, and more extensive results will be published at the 2022 meeting. We hope for an initial publication in 2022.</p> <p>PCOS study: After receiving Authority to Proceed on April 6, 2016, we worked with the NASA Shared Services Center (NSSC) to establish contract/funding for Mayo Clinic personnel, which was completed in July 2016.</p> <p>IRB documentation was developed and submitted for review by both NASA Johnson Space Center (JSC) and Mayo Clinic IRBs. This took a few iterations for modifications by each board to be approved by the other. IRB approval was obtained in October 2016.</p>

Subject recruitment and screening was initiated in November 2016. Because of the pandemic in 2020, recruitment was stopped before reaching a full complement of subjects. 55 subjects completed the study: 18 PCOS, 5 PCO+IIH, 22 IIH, and 10 Control. We had hoped to achieve n=20/group (thus a total of 80 subjects).

We are working with Dr. Geoffrey Ginsburg's group at Duke University to conduct statistical analyses of the genetic, biochemical, and ocular findings from this study. Initial findings were reported at the 2021 HRP IWS meeting, and more extensive results will be published at the 2022 meeting. We hope for an initial publication in 2022.

Bibliography Type:

Description: (Last Updated: 05/15/2025)